Výsledky vyhledávání - "Dylan Mezzio"

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis

Autor: Kim Campbell, Edward C. Li, Dylan Mezzio, David Campbell, Gary H. Lyman

Publikováno v: JCO Oncology Practice. 17:e1235-e1245

PURPOSE: Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1861737dbfaf1085ea4ae1c9f0ac8508
https://doi.org/10.1200/op.20.01047

Zobrazit plný text záznamu

Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder

Autor: Benjamin Parcher, Dylan Mezzio, Hilary F. Luderer, Fulton Velez, Robert Gerwien, Daniel C. Malone

Publikováno v: Postgraduate Medicine. 133:421-427

Background: The opioid epidemic continues to generate a significant mental and physical health burden on patients, and claims the life of almost 150 Americans daily. Making matters worse, an increase in relapses and/or opioid-related deaths has been

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c3c5b6d3ad22562c5517f7f57841f0
https://doi.org/10.1080/00325481.2021.1884471

Zobrazit plný text záznamu

Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk

Autor: Dylan Mezzio, Gary H. Lyman, Edward C. Li, Andrew Spargo, Kimberley J. Campbell

Publikováno v: Journal of Clinical Oncology. 38:73-73

73 Background: According to clinical practice guidelines, the threshold for routine myeloid growth factor (MGF) PP is a high risk (>20%) of developing FN. However, in response to the COVID-19 pandemic, a recent recommendation expands this threshold f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2c3f702175abdfe41e23f546ba437ad
https://doi.org/10.1200/jco.2020.38.29_suppl.73

Zobrazit plný text záznamu

Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk

Autor: Dylan Mezzio, Andrew Spargo, Edward C. Li, Kimberley J. Campbell, Gary H. Lyman

Publikováno v: Journal of Clinical Oncology. 38:e19401-e19401

e19401 Background: Patients with nonmetastatic NSCLC receiving platinum-based chemotherapy are at an intermediate risk (10-20%) of developing FN; clinical practice guidelines recommend assessing whether these patients have FN risk factors before cons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c158702eef07fe8aec58b61bf3cc3986
https://doi.org/10.1200/jco.2020.38.15_suppl.e19401

Zobrazit plný text záznamu

A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk

Autor: Dylan Mezzio, Edward C. Li, Gary H. Lyman, Kim Campbell, Sanjeev Balu

Publikováno v: Journal of Clinical Oncology. 37:107-107

107 Background: Historically, PP with a MGF was recommended in patients with a ≥40% risk for developing chemotherapy-induced FN, based on clinical and regimen-related factors. Previous economic studies provided evidence to lower the threshold to 20

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db844dca94559a153679db5cb7e8739a
https://doi.org/10.1200/jco.2019.37.27_suppl.107

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání